Kai Ming Medical -B (stock code: 2500) issued a notice on February 23, 2024, updating the progress of the re-licensing after the suspension of trading of shares since November 23, 2023. The announcement noted that the company's business is operating normally and has not been significantly affected by the unauthorized transaction incident, but the financial impact is being assessed. The Company has conducted a forensic investigation as requested by the Exchange and has taken the action recommended by the Special Committee. In addition, the company conducted an internal control system review and appointed a new chief financial officer. The Company is seeking the right person to fill vacancies for Independent Non-Executive Directors and Board Committees to comply with the Listing Rules. The shares will continue to suspend trading until the Replication Guidance is met.

Kai Ming Medical -B (stock code: 2500) issued a notice on February 23, 2024, updating the progress of the re-licensing after the suspension of trading of shares since November 23, 2023. The announcement noted that the company's business is operating normally and has not been significantly affected by the unauthorized transaction incident, but the financial impact is being assessed. The Company has conducted a forensic investigation as requested by the Exchange and has taken the action recommended by the Special Committee. In addition, the company conducted an internal control system review and appointed a new chief financial officer. The Company is seeking the right person to fill vacancies for Independent Non-Executive Directors and Board Committees to comply with the Listing Rules. The shares will continue to suspend trading until the Replication Guidance is met.